AstraZeneca: Tagrisso (osimertinib) With the Addition of Chemotherapy Approved in the US for Patients With EGFR-Mutated Advanced Lung Cancer
February 19, 2024
February 19, 2024
WILMINGTON, Delaware, Feb. 19 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca's TAGRISSO(R) (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
The approval following a Priority Review by the Food and Drug Administration (FDA) was based on . . .
AstraZeneca's TAGRISSO(R) (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
The approval following a Priority Review by the Food and Drug Administration (FDA) was based on . . .